# Comparative effectiveness and safety of direct ORal Anticoagulants in patients with atrial fibrillation: a standardiZed Observational data Network study (CORAZON)

PRESENTER: **Wallis** Lau

CORAZON is the **first study** to compare all the **four direct oral anticoagulants (DOACs)** among patients with **atrial fibrillation,** the most common heart rhythm disorder affecting **33 million** people worldwide.

Methods

- The **Orphan concepts** function helped to identify >100 concepts that should be but were not included at our first attempt to identify concepts using traditional methods

Population-Level Estimate
New-user cohort study
Propensity score modelling
P-Value Calibration

Evidence to guide DOAC use

Apixaban is less likely to cause bleeding compared to dabigatran, edoxaban, and rivaroxaban, with similar stroke risks

- the first and largest direct comparison among >600,000 patients with atrial fibrillation

Click or take a picture to download the full paper

Results

Figure 1. Number of patients in each database.
LPD France EMR and US Hospital Discharge Master have small (<1000) patient count for edoxaban and were not included in the analyses for edoxaban.
Abbreviations: LPD, Longitudinal Patient Data; EMR, Electronic Medical Record; DA, Disease Analyzer; IMRD: IQVIA Medical Research Data.


Ischemic stroke and/or systemic embolism
Intracranial haemorrhage
Gastrointestinal bleeding

Figure 2. Meta-analytic hazard ratios across all databases.

Join us!

(please click)

Wallis CY Lau, Kenneth KC Man, Carmen Olga Torre, Henry Morgan Stewart, Sarah Seager, Mui Van Zandt, Christian Reich, Ian CK Wong